Incoves

Solifenacin Succinate, the active ingredient in Incoves, is an antimuscarinic (muscarinic antagonist) presented as an oral tablet for oral use. It is prescribed to manage symptoms of overactive bladder, including urgency, frequency, and urge incontinence, in adult patients who experience these symptoms daily.

GNH USA supplies Incoves as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across multiple markets.

Incoves (solifenacin succinate) is used in the management of overactive bladder and related urinary symptoms.

- Overactive bladder: reduces urinary urgency and frequency by selectively relaxing the bladder’s detrusor muscle, improving daily comfort. - Urinary urgency: lessens sudden strong urges to void, allowing patients more control over bladder emptying. - Urinary frequency: decreases the number of daily voiding episodes, helping to normalize voiding patterns. - Urge urinary incontinence: helps prevent involuntary leakage that occurs with sudden urges, enhancing quality of life.

Common and serious adverse reactions have been reported with solifenacin succinate.

Common Side Effects: - Dry mouth: reduced salivation leading to a feeling of thirst. - Constipation: slowed intestinal transit causing hard stools. - Blurred vision: temporary visual disturbances. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness or imbalance.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder, potentially requiring catheterisation. - Tachycardia: increased heart rate that may be symptomatic. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests. - Angle‑closure glaucoma: acute eye pain and visual loss (rare).

When prescribing solifenacin succinate, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function: dose adjustment may be needed in impaired clearance. - Evaluate hepatic status: monitor liver enzymes in patients with liver disease. - Review concomitant anticholinergics: avoid additive anticholinergic burden. - Caution in patients with narrow-angle glaucoma: may exacerbate ocular pressure. - Monitor for urinary retention: especially in those with bladder outlet obstruction. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Solifenacin succinate may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase solifenacin plasma levels, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce effectiveness by lowering drug concentrations.

Moderate Interactions (Monitor Closely): - Other anticholinergic agents (e.g., diphenhydramine, oxybutynin): additive anticholinergic effects may increase side‑effects. - Digoxin: solifenacin may raise digoxin levels; monitor cardiac function. - QT‑prolonging drugs (e.g., erythromycin, fluoroquinolones): potential for cardiac rhythm disturbances. - Alcohol: may enhance dizziness and sedation.